Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Bofanglutide

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

Gan & Lee Pharmaceuticals · Phase 3 · Recruiting · Enrollment 420

NCT07150975

ArmPopulationDoseWeeksEstimandWeight change
GZR18 Dose Level 1Obesity or overweightn/rn/rn/rn/r
GZR18 Dose Level 2Obesity or overweightn/rn/rn/rn/r
Semaglutide(Wegovy® )2.4 mgObesity or overweight2.4 mgn/rn/rn/r